A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Phase of Trial: Phase II
Latest Information Update: 18 Mar 2019
At a glance
- Drugs Guadecitabine (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Astex Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 29 Dec 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov record.
- 06 Jan 2015 Planned End Date changed from 1 Feb 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov record.